BLCM - Bellicum inks license agreement with UNC Lineberger and Mass General

Bellicum Pharmaceuticals ([[BLCM]] +3.0%) has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center and Massachusetts General Hospital.The agreement covers certain intellectual property and technology rights regarding the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid.Under this agreement, upon out-license of each program to an industry partner, Bellicum will receive an upfront payment and be entitled to a percentage of certain consideration paid to the institutions by the industry partner and a single digit percent royalty on the global sales of the product.It covers four CAR-T programs incorporating Bellicum’s technology currently in development, two of which are owned by UNC Lineberger and two of which are co-owned by both institutions.Additional details of the financial arrangements are not disclosed.

For further details see:

Bellicum inks license agreement with UNC Lineberger and Mass General